Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + hydroxychloroquine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
A combination therapy consisting of methotrexate (MTX) and hydroxychloroquine (HCQ) primarily used for the treatment of rheumatoid arthritis (RA). This combination has been shown to be more potent than methotrexate monotherapy. The enhanced efficacy is attributed to a pharmacokinetic interaction where hydroxychloroquine increases the bioavailability of methotrexate, resulting in higher drug exposure while potentially reducing peak concentrations that may cause acute side effects.
- Other names
- MTX + HCQ
02
Targets
TLR9 (Toll-like receptor 9)DHFR (Dihydrofolate reductase)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on methotrexate + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + hydroxychloroquine.